Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: A phase II study

British Journal of Cancer

Volumn 94, Issue 10, 2006, Pages 1389-1394

  Van Meerten, E ^a   Muller, K ^a   Tilanus, H W ^a   Siersema, P D ^a   Eijkenboom, W M H ^a   Van Dekken, H ^a   Tran, T C K ^a   Van Der Gaast, A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemoradiotherapy; Chemotherapy; Combined modality treatment; Oesophageal carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CLEMASTINE; DEXAMETHASONE; FLUOROURACIL; PACLITAXEL; RANITIDINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FEVER; HUMAN; HUMAN TISSUE; LETHARGY; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PREOPERATIVE CARE; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 33646825826     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603134     Document Type: Article

References (34)

1. Apinop C, Puttisak P, Preecha N (1994) A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 41: 391-393
2. Avendano CE, Flume PA, Silvestri GA, King LB, Reed CE (2002) Pulmonary complications after esophagectomy. Ann Thorac Surg 73: 922-926
3. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23: 4330-4337
4. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337: 161-167
5. Brown WA, Thomas J, Gotley D, Burmeister BH, Lim KH, Martin I, Walpole ET, Thomson DB, Harvey JA, Smithers BM (2004) Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg 91: 199-204
6. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group (2005) Surgery alone vs chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6: 659-668
7. Choi N, Park SD, Lynch T, Wright C, Ancukiewicz M, Wain J, Donahue D, Mathisen D (2004) Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. Int J Radiat Oncol Biol Phys 60: 111-122
8. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T (1998) Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16: 3316-3322
9. Choy H, Devore III RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH (2000) A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 47: 931-937
10. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD (1993) Investigation of taxol as a potential radiation sensitizer. Cancer 71: 3774-3778
11. Crozier TA, Sydow M, Siewert JR, Braun U (1992) Postoperative pulmonary complication rate and long-term changes in respiratory function following esophagectomy with esophagogastrostomy Acta. Anaesthesiol Scand 36: 10-15
12. Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxi A, Camma C (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53: 925-930
13. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam Jr JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA (2002) Treatment outcomes of resected esophageal cancer. Ann Surg 236: 376-384; discussion 384-385
14. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ (2001) Transthoracic vs transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 72: 306-313
15. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347: 1662-1669
16. International Union Against Cancer (UICC) (2002) TNM Classification of Malignant Tumours. Wiley-Liss, New York
17. Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Muller KM (1997) Tumour regression in non-small-cell lung cancer following neo-adjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123: 469-477
18. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS (2003) Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 10: 754-761
19. Kaplan B, Altynbas M, Eroglu C, Karahacioglu E, Er O, Ozkan M, Bilgin M, Canoz O, Gulmez I, Gulec M (2004) Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC). Am J Clin Oncol 27: 603-610
20. Kelley ST, Coppola D, Karl RC (2004) Neoadjuvant chemoradiotherapy is not associated with a higher complication rate vs surgery alone in patients undergoing esophagectomy. J Gastrointest Surg 8: 227-231; discussion 231-232
21. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339: 1979-1984
22. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J (2001) Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 19: 442-447
23. Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, Boutin D, Campion JP, Launois B (1994) A randomized study of chemotherapy, radiation therapy, and surgery vs surgery for localized squamous cell carcinoma of the esophagus. Cancer 73: 1779-1784
24. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA (1996) Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 56: 5198-5204
25. Medical Research Council Oesophageal Cancer Working Group (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359: 1727-1733
26. Polee MB, Tilanus HW, Eskens FA, Hoekstra R, Van der Burg ME, Siersema PD, Stoter G, Van der Gaast A (2003) Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus. Ann Oncol 14: 1253-1257
27. Ratanatharathorn V, Lorvidhaya V, Maoleekoonpairoj S, Phromratanapongse P, Sirilerttrakul S, Kraipiboon P, Cheirsilpa A, Tangkaratt S, Srimuninnimit V, Pattaranutaporn P (2001) Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Lung Cancer 31: 257-265
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
29. Tishler RB, Schiff PB, Geard CR, Hall EJ (1992) Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22: 613-617
30. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M (2001) Randomized trial of preoperative chemoradiation vs surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313
31. Urschel JD, Vasan H (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185: 538-543
32. van Lanschot JJ, Hulscher JB, Buskens CJ, Tilanus HW, ten Kate FJ, Obertop H (2001) Hospital volume and hospital mortality for esophagectomy. Cancer 91: 1574-1578
33. Van Meerten E, Van der Gaast A (2005) Systemic treatment for oesophageal cancer. Eur J Cancer 41: 664-672
34. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335: 462-467